Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants
Pegu, A.; O'Connell, S. E.; Schmidt, S. D.; O'Dell, S.; Talana, C. A.; Lai, L.; Albert, J.; Anderson, E.; Bennett, H.; Corbett, K.; Flach, B.; Jackson, L.; Leav, B.; Ledgerwood, J. E.; Luke, C. J.; Makowski, M.; Roberts, P. C.; Roederer, M.; Rebolledo, P. A.; Rostad, C. A.; Rouphael, N. G.; Shi, W.; Wang, L.; Widge, A. T.; Yang, E. S.; Beigel, J. H.; Graham, B. S.; Mascola, J. R.; Suthar, M. S.; McDermott, A.; Doria-Rose, N. A.
Show abstract
SARS-CoV-2 mutations may diminish vaccine-induced protective immune responses, and the durability of such responses has not been previously reported. Here, we present a comprehensive assessment of the impact of variants B.1.1.7, B.1.351, P.1, B.1.429, and B.1.526 on binding, neutralizing, and ACE2-blocking antibodies elicited by the vaccine mRNA-1273 over seven months. Cross-reactive neutralizing responses were rare after a single dose of mRNA-1273. At the peak of response to the second dose, all subjects had robust responses to all variants. Binding and functional antibodies against variants persisted in most subjects, albeit at low levels, for 6 months after the primary series of mRNA-1273. Across all assays, B.1.351 had the greatest impact on antibody recognition, and B.1.1.7 the least. These data complement ongoing studies of clinical protection to inform the potential need for additional boost vaccinations. One-Sentence SummaryMost mRNA-1273 vaccinated individuals maintained binding and functional antibodies against SARS-CoV-2 variants for 6 months.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Immunity to seasonal coronavirus spike proteins does not protect from SARS-CoV-2 challenge in a mouse model but has no detrimental effect on protection mediated by COVID-19 mRNA vaccination 96%
- Stabilized dengue virus 2 envelope subunit vaccine redirects the neutralizing antibody response to all E-domains 96%
- Nucleoside-modified mRNA-based influenza vaccines circumvent problems associated with H3N2 vaccine strain egg-adaptation 95%
Similar papers in this journal
- Previous Infection Combined with Vaccination Produces Neutralizing Antibodies With Potency Against SARS-CoV-2 Variants 97%
- Murine monoclonal antibodies against RBD of SARS-CoV-2 neutralize authentic wild type SARS-CoV-2 as well as B.1.1.7 and B.1.351 viruses and protect in vivo in a mouse model in a neutralization dependent manner 96%
- Greater breadth of vaccine-induced immunity in females than males is mediated by increased antibody diversity in germinal center B cells 96%
Similar papers in this journal
- High resolution linear epitope mapping of the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 mRNA vaccine recipients 95%
- Ancestral SARS-CoV-2 driven antibody repertoire diversity in an unvaccinated individual correlates with expanded neutralization breadth 94%
- SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates Against Symptomatic Infection 94%
Similar papers in this journal
- Immunogenic Amino Acid Motifs and Linear Epitopes of COVID-19 mRNA Vaccines 96%
- Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review 95%
- Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2 95%
Similar papers in this journal
- Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination 96%
- Clinical utility of Elecsys Anti-SARS-CoV-2 S assay in COVID-19 vaccination: An exploratory analysis of the mRNA-1273 phase 1 trial 95%
- Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.